Beneficial Effects of Chromium(III) and Vanadium Supplements in Diabetes

Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome

Volumn , Issue , 2012, Pages 381-391

  Vincent, John B ^a  

^a UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884078309     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385083-6.00030-9     Document Type: Chapter

References (50)

1. Schwarz K., Mertz W. Chromium(III) and the glucose tolerance factor. Arch Biochem Biophys 1959, 85:292-295.
2. Vincent J.B. Chromium: Celebrating 50 years as an essential element?. Dalton Trans 2010, 39. 3878-3794.
3. th Ed. Report of the Committee on Dietary Allowances, Division of Biological Sciences, Assembly of Life Science, Food and Nutrition Board, Commission on Life Science, National Research 1980, National Academy Press, Washington, DC.
4. National Research Council Dietary Reference Intakes for Vitamin A, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. A Report of the Panel on Micronutrients, Subcommittee on Upper Reference Levels of Nutrients and of Interpretations and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes 2002, National Academy of Sciences, Washington, DC.
5. Di Bona K.R., Love S., Rhodes N.R., McAdory D., Sinha S.H., Kern N., Kent J., Strickland J., Wilson A., Beaird J., Ramage J., Rasco J.F., Vincent J.B. Chromium is not an essential trace element for mammals: Effects of a "low-chromium" diet. J Biol Inorg Chem 2011, 16:381-390.
6. Striffler J.S., Law J.S., Polansky M.M., Bhathena S.J., Anderson R.A. Chromium improves insulin response to glucose in rats. Metabolism 1995, 44:1314-1320.
7. Striffler J.S., Polansky M.M., Anderson R.A. Dietary chromium decreases insulin resistance in rats fed a high fat mineral imbalanced diet. Metabolism 1998, 47:396-400.
8. Jeejeebhoy K.N. Chromium and parenteral nutrition. J Trace Elem Exp Med 1999, 12:85-89.
9. Anderson R.A., Kozlovsky A.S. Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr 1985, 41:1177-1183.
10. Morris B.W., Kemp G.J., Hardisty C.A. Plasma chromium and chromium excretion in diabetes. Clin Chem 1985, 31:334-335.
11. Dowling H.J., Offenbacher E.G., Pi-Sunyer F.X. Absorption of inorganic, trivalent chromium from the vascularly perfused rat small intestine. J Nutr 1989, 119:1138-1145.
12. Rhodes N.R., McAdory D., Love S., DiBona K.R., Chen Y., Ansorge K., Hira J., Kent J., Lara P., Rasco J.F., Vincent J.B. Urinary chromium loss associated with diabetes is offset by increases in absorption. J Inorg Biochem 2010, 104:790-797.
13. Feng W., Ding W., Qian Q., Chai Z. Use of the enriched stable isotope Cr-50 as a tracer to study the metabolism of chromium(III) in normal and diabetic rats. Biol Trace Elem Res 1998, 63:129-138.
14. Toepfer E.W., Mertz W., Polansky M.M., Roginski E.E., Wolf W.R. Preparation of chromium-containing material of glucose tolerance factor activity from brewer's yeast extracts and by synthesis. J Agric Food Chem 1977, 25. 162-162.
15. Vincent J.B. The bioinorganic chemistry of chromium. Polyhedron 2001, 20:1-26.
16. Vincent J.B., Stearns D.M. The bioinorganic chemistry of chromium: essentiality, therapeutic agent, toxin, carcinogen? 2011, Wiley-Blackwell, Chichester.
17. Food and Drug Administration. Qualified Health Claims: Letter of Enforcement Discretion-Chromium Picolinate and Insulin Resistance (Docket No. 2004Q-0144), 2005. http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthCla ims/ucm073017.htm.
18. Cefalu W.T., Bell-Farrow A.D., Stegner J., Wang Z.Q., King T., Morgan T., Terry J.G. Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med 1999, 12:71-83.
19. Balk E.M., Tatsioni A., Lichenstein A.H., Lau J., Pittas A.G. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007, 30:2154-2163.
20. Anderson R.A., Cheng N.C., Bryden N.A., Polansky M.M., Cheng N., Chi J., Feng J. Elevated levels of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997, 46:1786-1791.
21. American Diabetes Association Standards of medical care in diabetes-2010. Diabetes Care 2010, 23(Suppl. 1):S11-S61.
22. Cefalu W.T., Rood J., Pinsonat P., Qin J., Sereda O., Levitan L., Abderson R.A., Zhang X.H., Martin J.M., Wang Z.Q., Newcomer B. Characterization of the metabolic and physiological response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism 2010, 59:755-762.
23. Stout M.D., Nyska A., Collins B.J., Witt K.L., Kissling G.E., Malarkey D.E., Hooth M.J. Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years. Food Chem Toxicol 2009, 47:729-733.
24. European Food Safety Authority Scientific opinion on the safety of trivalent chromium as a nutrient added for nutritional purposes to foodstuffs for particular nutritional uses and foods intended for the general population (including food supplement). EFSA J 2010, 8:1-46.
25. Schwarz K., Milne D.B. Growth effects of vanadium in the rat. Science 1971, 4007:426-428.
26. Uthus E.O., Nielsen F.H. Effect of vanadium, iodine and their interaction on growth, blood variables, liver trace elements and thyroid status indices in rats. Magnes Trace Elem 1990, 9:219-226.
27. Nielsen F.H. Nutritional requirements for boron, silicon, vanadium, nickel, and arsenic: current knowledge and speculation. FASEB J 1991, 5:2661-2667.
28. Myron D.R., Zimmerman T.J., Shuler T.R., Klevay L.M., Lee D.M., Nielsen F.H. Intake of nickel and vanadium by humans. A survey of selected diets. Am J Clin Nutr 1978, 31:527-531.
29. Pennington J.A., Jones J.W. Molybdenum, nickel, cobalt, vanadium, and strontium in total diets. J Am Diet Assoc 1987, 87:1644-1650.
30. 2+ compounds. J Biol Inorg Chem 2010, 15:825-839.
31. Thompson K.H., Orvig C. Vanadium in diabetes: 100 years from Phase 0 to Phase I. J Inorg Biochem 2006, 100:1925-1935.
32. Mohammad A., Bhanot S., McNeill J.H. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle. Mol Cell Biochem 2001, 223:103-108.
33. Shisheva A., Shechter Y. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry 1992, 31:8059-8063.
34. Vankatesan N., Avidan A., Davidson M.B. Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes 1991, 40:492-498.
35. Meyerovitch J., Baker J.M., Kahn C.R. Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. J Clin Invest 1989, 84:976-983.
36. Pugazhenthi S., Tanha F., Dahl B., Khandelwal R.L. Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver. Mol Cell Biochem 1995, 153:125-129.
37. Mohammad A., Wang J., McNeill J.H. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo. Mol Cell Biochem 2002, 229:125-128.
38. 4) as the active component. J Inorg Biochem 2003, 96:321-330.
39. Fantus I.G., Ahmad F., Deragon G. vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes: evidence for transduction of amplitude of signaling into duration of response. Diabetes 1994, 43:375-383.
40. Lu B., Ennis D., Lai R., Bogdanovic E., Nikolov R., Salamon L., Fantus, Le-Tien C., Fantus I.G. Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated with oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). J Biol Chem 2001, 276:35589-35598.
41. Medhi M.Z., Pandey S.K., Theberge J.-F., Srivastava A.K. Insulin signal mimicry as a mechanism for the insulin-like effect of vanadium. Cell Biochem Biophys 2006, 44:73-81.
42. Srivastava A.K., Mehdi M.Z. Insulin-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 2005, 22:2-13.
43. Shechter Y., Goldwaser I., Mironchik M., Fridkin M., Gefel D. Historic perspective and recent developments on the insulin-like actions of vanadium; towards developing vanadium-based drugs for diabetes. Coord Chem Rev 2003, 237:3-11.
44. Thompson K.H., Orvig C. Vanadium compounds in the treatment of diabetes. Met Ions Biol Syst 2004, 41:221-252.
45. Thompson K.H., Orvig C. Coordination chemistry of vanadium in metallopharmaceutical candidate compounds. Coord Chem Rev 2001, 219-221:1033-1053.
46. 48V-labeled compounds in the rat. J Appl Physiol 1998, 84:569-575.
47. Vardatsikos G., Medhi M.Z., Srivastava A.K. Bis(maltolato)-oxovanadium(IV)-induced phosphorylation of PKB, GSK-3 and FOX01 contributes to its glucoregulatory responses (Review). Int J Mol Med 2009, 24:303-309.
48. Sanna D., Micera G., Garribba E. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in blood serum. Inorg Chem 2010, 49:174-187.
49. Smith D.M., Pickering R.M., Lewith G.T. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. Q J Med 2008, 101:351-358.
50. Thompson K.H., Lichter J., LeBel C., Scaife M.C., McNeill J.H., Orvig C. Vanadium treatment of type 2 diabetes: A view to the future. J Inorg Biochem 2009, 103:554-558.